Low Risk of Hyperprogression with First-LineChemoimmunotherapy for Advanced Non-Small Cell Lung Canc

Low Risk of Hyperprogression with First-Line

Chemoimmunotherapy for Advanced Non-Small Cell

Lung Cancer: Pooled Analysis of 7 Clinical Trials

Lee X. Li, Federico Cappuzzo, Ignacio Matos, Mark A. Socinski,

Ashley M. Hopkins, Michael J. Sorich

Για να διαβάσετε το άρθρο ακολουθήστε το παρακάτω λινκ:

LOW RISK OF HYPERPROGRESSION WITH FIRST LINE CHEMOIMMUNOTHERAPY FOR ADVANCED NSCLC

.pdf

Download PDF • 492KB